aTyr Pharma Inc (LIFE)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
John D. Mendlein
Employees:
42
3545 JOHN HOPKINS COURT, STE #250, SAN DIEGO, CA 92121
858-731-8389

aTyr Pharma, Inc. develops protein therapeutics and novel class of biologic drugs. It plans to build a pipeline of innovative therapeutic products based on Physiocrine biology. The company has established a dominant intellectual property estate to protect the core therapeutics as well as associated diagnostics. aTyr Pharma was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler in 2005 and is headquartered in San Diego, CA.

Data derived from most recent annual or quarterly report
Market Cap 79.496 Million Shares Outstanding27.796 Million Avg 30-day Volume 87.115 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.42
Price to Revenue0.0 Debt to Equity0.0 EBITDA-37.334 Million
Price to Book Value1.5231 Operating Margin0.0 Enterprise Value51.259 Million
Current Ratio16.449 EPS Growth0.225 Quick Ratio15.807
1 Yr BETA 0.9428 52-week High/Low 13.1 / 2.6 Profit Margin0.0
Operating Cash Flow Growth-61.1619 Altman Z-Score8.8055 Free Cash Flow to Firm -28.247 Million
Earnings Report2022-08-10

Are you looking for these stocks instead?

View SEC Filings from LIFE instead.

View recent insider trading info

Funds Holding LIFE (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding LIFE BETA

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Events (8k)

  • 8-K: filed on 2022-05-17:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-16:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-09:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-29:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 1.02: Termination of a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K/A: filed on 2022-04-14:
    Item 8.01: Other Events
  • 8-K: filed on 2022-04-13:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-14:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-16:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-09-13:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    BROADFOOT JILL MARIE CHIEF FINANCIAL OFFICER

    • Officer
    87,637 2022-05-24 3

    DENYES NANCY GENERAL COUNSEL

    • Officer
    91,544 2022-05-24 2

    SHUKLA SANJAY PRESIDENT AND CEO

    • Officer
    • Director
    516,280 2022-05-24 4

    CLARKE JOHN K

    • Director
    6,000 2022-04-26 1

    SCHIMMEL PAUL

    • Director
    6,000 2022-04-26 2

    COUGHLIN TIMOTHY

    • Director
    6,000 2022-04-26 1

    ZAKNOEN SARA

    • Director
    6,000 2022-04-26 1

    GROSS JANE A

    • Director
    6,000 2022-04-26 1

    LUCAS SVETLANA

    • Director
    6,000 2022-04-26 1

    HATFIELD JEFFREY S.

    • Director
    0 2020-05-06 0

    BLAIR JAMES C

    • Director
    0 2019-05-08 0

    MENDLEIN JOHN

    • Director
    0 2019-05-08 0

    AMANULLAH ASHRAF SEE REMARKS

    • Officer
    No longer subject to file 2018-05-31 0

    NASHAT AMIR

    • Director
    0 2018-05-15 0

    ECOR1 CAPITAL FUND QUALIFIED, L.P.

    • 10% Owner
    No longer subject to file 2018-05-14 0

    BLACKBURN STAN

    • SEE REMARKS
    11,954 2018-03-20 0

    BLAKE JOHN T SENIOR VICE PRESIDENT, FINANCE

    • Officer
    1,932 2018-02-06 0

    KING DAVID JOHN CHIEF SCIENTIFIC OFFICER

    • Officer
    0 2018-02-06 0

    AKKARAJU SRINIVAS

    • Director
    0 2017-05-09 0

    GOLDBERG MARK ALAN

    • Director
    0 2017-05-09 0

    RAVINDRAN SANUJ K. CHIEF BUSINESS OFFICER

    • Officer
    0 2017-02-07 0

    MATSUOKA GROVE SEE REMARKS

    • Officer
    0 2017-02-07 0

    CUBITT ANDREW VP, PRODUCT PROTECTION

    • Officer
    0 2016-09-13 0

    FALBERG KATHRYN E

    • Director
    0 2016-05-24 0

    BLACKBURN KELLY VP, CLINICAL AFFAIRS

    • Officer
    0 2016-03-28 0

    CHRZANOWSKI HOLLY D. SEE REMARKS

    • Officer
    0 2016-01-27 0

    MCKEW JOHN C. VP, RESEARCH

    • Officer
    0 2016-01-27 0

    ASHLOCK MELISSA A. SEE REMARKS

    • Officer
    0 2016-01-27 0

    GRAHAM MARCY SEE REMARKS

    • Officer
    0 2016-01-04 0

    RAMSDELL FRED VP, IMMUNOLOGY

    • Officer
    0 2015-10-01 0

    FLYNN JAMES E

    DEERFIELD MGMT L.P.

    DEERFIELD MANAGEMENT CO

    DEERFIELD SPECIAL SITUATIONS FUND, L.P.

    DEERFIELD MGMT III, L.P.

    DEERFIELD PRIVATE DESIGN FUND III, L.P.

    • 10% Owner
    • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
    No longer subject to file 2015-05-12 0

    DP VIII ASSOCIATES, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    • Director
    • 10% Owner
    13,414 2015-05-12 0

    DOMAIN PARTNERS VIII, L.P.

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    • Director
    • 10% Owner
    1,807,820 2015-05-12 0

    CHP II LP

    CHP II MANAGEMENT, LLC

    HULL BRANDON H

    PARK JOHN JOSEPH

    • 10% Owner
    No longer subject to file 2015-05-12 0

    ALTA PARTNERS VIII, L.P.

    ALTA PARTNERS MANAGEMENT VIII, LLC

    JANNEY DANIEL

    CHAMPSI FARAH

    NOHRA GUY P

    • 10% Owner
    No longer subject to file 2015-05-12 0

    SOFINNOVA VENTURE PARTNERS IX, L.P.

    SOFINNOVA MANAGEMENT IX, L.L.C.

    HEALY JAMES

    POWELL MICHAEL

    MEHRA ANAND

    • 10% Owner
    No longer subject to file 2015-05-12 0

    POLARIS VENTURE MANAGEMENT CO. V, L.L.C.

    POLARIS VENTURE PARTNERS V, L.P.

    POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P.

    POLARIS VENTURE PARTNERS FOUNDERS' FUND V, L.P.

    POLARIS VENTURE PARTNERS SPECIAL FOUNDERS' FUND V, L.P.

    • 10% Owner
    No longer subject to file 2015-05-12 0

    DOMAIN ASSOCIATES

    BLAIR JAMES C

    DOVEY BRIAN H

    TREU JESSE I

    SCHOEMAKER KATHLEEN K

    VITULLO NICOLE

    HALAK BRIAN K

    KAMDAR KIM P.

    • Director
    • 10% Owner
    12,572 2015-05-06 0

    SOFINNOVA VENTURE PARTNERS IX, L.P.

    SOFINNOVA MANAGEMENT IX, L.L.C.

    HEALY JAMES

    POWELL MICHAEL

    AKKARAJU SRINIVAS

    MEHRA ANAND

    • 10% Owner
    0 2015-05-06 0

    CHEREAU FREDERIC COO & PRESIDENT

    • Officer
    12,867 2015-05-06 0

    WEINER DAVID M. CHIEF MEDICAL OFFICER

    • Officer
    5,028 2015-05-06 0

    ANDREWS RONALD ASBURY PRESIDENT, MEDICAL SCIENCES

    • Officer
    3,330 2012-04-27 0

    STEVENSON MARK PRESIDENT & COO

    • Officer
    49,699 2011-08-22 0

    PESCOVITZ ORA H.

    • Director
    1,133 2011-08-22 0

    LUCIER GREGORY T CHIEF EXECUTIVE OFFICER

    • Officer
    335,878 2011-08-05 0

    MATRICARIA RONALD A

    • Director
    70,000 2011-08-01 0

    LONGFIELD WILLIAM H

    • Director
    13,000 2009-05-11 0

    ADAM GEORGE F JR

    • Director
    2,747 2009-05-08 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    SHUKLA SANJAY - Director - Officer PRESIDENT AND CEO

    2022-05-26 16:30:16 -0400 2022-05-24 A 516,280 a 516,280 direct

    BROADFOOT JILL MARIE - Officer CHIEF FINANCIAL OFFICER

    2022-05-26 16:32:49 -0400 2022-05-24 A 75,347 a 75,347 direct

    DENYES NANCY - Officer GENERAL COUNSEL

    2022-05-26 16:34:50 -0400 2022-05-24 A 88,097 a 88,097 direct

    CLARKE JOHN K - Director

    2022-04-28 19:39:09 -0400 2022-04-26 A 6,000 a 6,000 direct

    COUGHLIN TIMOTHY - Director

    2022-04-28 19:42:58 -0400 2022-04-26 A 6,000 a 6,000 direct

    GROSS JANE A - Director

    2022-04-28 19:46:57 -0400 2022-04-26 A 6,000 a 6,000 direct

    LUCAS SVETLANA - Director

    2022-04-28 19:50:16 -0400 2022-04-26 A 6,000 a 6,000 direct

    SCHIMMEL PAUL - Director

    2022-04-28 19:53:12 -0400 2022-04-26 A 6,000 a 6,000 direct

    ZAKNOEN SARA - Director

    2022-04-28 19:57:39 -0400 2022-04-26 A 6,000 a 6,000 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ATYR PHARMA INC LIFE 2022-06-24 22:15:03 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 21:45:03 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 21:15:04 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 20:45:03 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 20:15:03 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 19:45:03 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 19:15:03 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 18:45:03 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 18:15:04 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 17:45:03 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 17:15:03 UTC 0.7512 0.8188 1100000
    ATYR PHARMA INC LIFE 2022-06-24 16:45:03 UTC 0.7656 0.8044 1100000
    ATYR PHARMA INC LIFE 2022-06-24 16:15:03 UTC 0.7656 0.8044 1100000
    ATYR PHARMA INC LIFE 2022-06-24 15:45:03 UTC 0.7656 0.8044 450000
    ATYR PHARMA INC LIFE 2022-06-24 15:15:03 UTC 0.7656 0.8044 450000
    ATYR PHARMA INC LIFE 2022-06-24 14:45:03 UTC 0.7734 0.7966 450000
    ATYR PHARMA INC LIFE 2022-06-24 14:15:03 UTC 0.7734 0.7966 450000
    ATYR PHARMA INC LIFE 2022-06-24 13:45:03 UTC 0.7734 0.7966 450000
    ATYR PHARMA INC LIFE 2022-06-24 13:15:03 UTC 0.7734 0.7966 450000
    ATYR PHARMA INC LIFE 2022-06-24 12:45:03 UTC 0.7734 0.7966 450000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund LIFE -16795.0 shares, $-95563.55 2022-01-31 N-PORT
    RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund LIFE -2864.0 shares, $-15322.4 2022-03-31 N-PORT

    Elevate your investments